Nucleic Acid-based Cancer Therapy for Advanced-stage Solid Tumors: A Brief Overview
Archives of Advances in Biosciences,
Vol. 15 No. 1 (2024),
24 January 2024
,
Page 1-6
https://doi.org/10.22037/aab.v15i1.45504
Abstract
Introduction: The management of advanced-stage solid tumors remains a formidable challenge in oncology, often necessitating a combination of treatment modalities with limited efficacy. Nucleic acid-based drugs have emerged as promising therapeutic options, offering novel approaches to combat treatment-resistant tumors. This editorial review briefly analyzes viral and non-viral nucleic acid-based treatments for solid tumors, including their development, clinical activity, mechanisms of action, and prospects. Viral vectors, such as adenoviruses and lentiviruses, enable the delivery of therapeutic genes directly into tumor cells or the modulation of the tumor microenvironment, resulting in regulatory approvals for several gene therapies. Non-viral delivery systems, including lipid nanoparticles and polymer-based carriers, offer alternative strategies for transporting therapeutic nucleic acids into tumor cells, with precise drug release and targeting control.
Materials and Methods: The literature review is based on searches of the PubMed database, Web of Science, Scopus, and Google Scholar using specific keywords. The article is based on manuscripts published between 2021 and 2024.
Results: The mechanistic actions of nucleic acid-based drugs are diverse, encompassing direct tumor cell killing, modulation of the immune response, and inhibition of oncogenic pathways. Importantly, these therapeutic approaches demonstrate a favorable safety profile compared to traditional chemotherapy agents, minimizing off-target effects and reducing adverse events. The tumor microenvironment significantly influences the effectiveness of nucleic acid-based therapies, requiring strategies to improve drug delivery and overcome resistance mechanisms. Ongoing clinical trials, preclinical studies, and advancements in manufacturing and stability technologies are expected to drive the next generation of nucleic acid agents, ensuring widespread accessibility and clinical utility.
Conclusion: Nucleic acid-based drugs represent a transformative approach to cancer therapy, potentially revolutionizing treatment outcomes and ushering in an era of precision medicine in oncology.
- Antisense oligonucleotide
- Nucleic acid based drugs
- Solid tumors
- Tumor microenvironment
- Viral/non-viral approach
How to Cite
References
Wang F, Li P, Chu HC, Lo PK. Nucleic Acids and Their Analogues for Biomedical Applications. Biosensors.2022;12(2):93. [DOI:10.3390/bios12020093]
Huayamares SG, Loughrey D, Kim H, Dahlman JE, Sorscher EJ. Nucleic acid-based drugs for patients with solid tumours. Nature Reviews Clinical Oncology. 2024:1-21.[DOI: 10.1038/s41571-024-00883-1]
de la Fuente IF, Sawant SS, Tolentino MQ, Corrigan PM, Rouge JL. Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers. Front Chem. 2021;9:613209. [DOI:10.3389/fchem.2021.613209]
Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, Mackiewicz A. (2023). Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells, 12(17), 2159. [DOI:10.3390/cells12172159]
dos Santos Fonseca LM, Machado BA, Oliveira FO, de Jesus Santos JR, da Silva JW, Hodel KV, Rosatti BG, Pinto CD, Soares MB. An overview on recent patents and technologies on nanoparticles for nucleic acid delivery. Expert Opinion on Therapeutic Patents. 2024;34(3):171-86.. [DOI:10.1080/13543776.2024.2338097]
Taibi T, Cheon S, Perna F, Vu LP. mRNA-based therapeutic strategies for cancer treatment. Molecular Therapy. 2024.[DOI: 10.1016/j.ymthe.2024.04.035]
Yamada Y. Nucleic acid drugs—current status, issues, and expectations for exosomes. Cancers. 2021 Oct 5;13(19):5002. [DOI:10.3390/cancers13195002]
Kaniowski D, Kulik K, Suwara J, Ebenryter-Olbińska K, Nawrot B. Boron Clusters as Enhancers of RNase H Activity in the Smart Strategy of Gene Silencing by Antisense Oligonucleotides. Int J Mol Sci. 2022;23(20):12190. [DOI:10.3390/ijms232012190]
Wang P, Zhou Y, Richards AM. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. Theranostics. 2021;11(18):8771-96. [DOI: 10.7150/thno.62642] [PMID] [PMCID]
Chen Y, Li Y, Li C, Zhang D, Liu Y, Zhang J, Guan S, Ding X, Xiao Q. The current perspective and opportunities of small nucleic acid‐based therapeutics. Drug Development Research. 2024;85(2):e22164. [DOI: 10.1002/ddr.22164]
Monaci S, Coppola F, Filippi I, Falsini A, Carraro F, Naldini A. Targeting hypoxia signaling pathways in angiogenesis. Frontiers in Physiology. 2024;15:1408750. [DOI: 10.3389/fphys.2024.1408750]
Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, al. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. International Journal of Nanomedicine. 2021:5811-29. [DOI:10.2147/IJN.S321416]
Wessel KM, Kaplan RN. Targeting tumor microenvironment and metastasis in children with solid tumors. Curr Opin Pediatr. 2022;34(1):53-60. [DOI:10.1097/MOP.0000000000001082] [PMID] [PMCID]
Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers.2021;13(9):2053. [DOI:10.3390/cancers13092053]
Eturi A, Bhasin A, Zarrabi KK, Tester WJ. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. Molecules. 2024;29(8):1896. [DOI:10.3390/molecules29081896]
Sheikhlary S, Lopez DH, Moghimi S, Sun B. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review. Biomolecules. 2024;14(4):503. [DOI:10.3390/biom14040503]
Noh I, Lee K, Rhee YS. Microneedle systems for delivering nucleic acid drugs. J Pharm Investig. 2022;52(3):273-92. [DOI:10.1007/s40005-021-00558-4]
Gubu A, Zhang X, Lu A, Zhang B, Ma Y, Zhang G. Nucleic acid amphiphiles: Synthesis, properties, and applications. Mol Ther Nucleic Acids. 2023;33:144-163. [DOI:10.1016/j.omtn.2023.05.022]
Goyenvalle A, Jimenez-Mallebrera C, van Roon W, et al. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Ther. 2023;33(1):1-16. [DOI:10.1089/nat.2022.0061]
- Abstract Viewed: 1041 times
- pdf Downloaded: 178 times